HCW Biologics prices $1.5 million private placement with existing investor
On September 23, 2026, HCW Biologics agreed to sell 903,614 units to an existing institutional investor for approximately $1.5 million in gross proceeds before offering expenses. Each unit pairs a pre-funded warrant with the right to receive a common warrant at $1.66 per share, which is issuable only after stockholder approval that the company is obligated to seek. The company plans to use the proceeds for working capital, clinical development and general corporate purposes, and it agreed to register the resale of the shares underlying the warrants, which could add shares to the market.
Key points
- 903,614 units sold at $1.6599 per unit; pre-funded warrants have a $0.0001 exercise price
- Common warrants for up to 903,614 shares, exercisable at $1.66 per share for 5.5 years after issuance, subject to stockholder approval under Nasdaq Rule 5635(d)
- Maxim Group LLC is the sole placement agent
- Company must file a resale registration statement within 15 trading days after closing and use commercially reasonable efforts to have it declared effective within 60 days
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 24, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.